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HIV Reservoir MaintenanceHIV establishes a latent reservoir early in infection that is resistant to anti-retroviral therapy and has a slow
rate of decay. It is thought that the majority of HIV DNA in treated patients is integrated since unintegrated
HIV DNA appears to be unstable. Thus, to monitor the HIV latent reservoir, total HIV DNA is commonly
measured in PBMC from infected individuals. We investigated how often total approaches integrated HIV
DNA in treated patients. To do this, we ﬁrst assessed how accurate our integration assay is and determined
the error in our measurements of total and integrated HIV DNA. We demonstrated an excess of total over
integrated HIV DNA was present in a subset of patients, suggesting that measurements of total HIV DNA do
not always correlate to the level of integration. Determining the cause of this excess and its frequency may
have important implications for understanding HIV latent reservoir maintenance.hn Morgan Bldg., Philadelphia,
herty).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Integration into the host cell genome is a fundamental character-
istic of retroviruses. Although some gene expression occurs from
unintegrated retroviral DNA, integrated DNA serves as the main
template for efﬁcient gene transcription and viral replication (Ansari-
Lari et al., 1995; Cara et al., 1995; Cofﬁn, 1997; Engelman et al., 1995;
Englund et al., 1995; Sakai et al., 1993; Stevenson et al., 1990a,b;
Wiskerchen and Meusing, 1995). This characteristic allows the
provirus to be stably expressed by the host machinery and to persist
in the infected cell indeﬁnitely. This is particularly important for the
survival of HIV in infected individuals. By integrating its genome, HIV
can be persistently produced from cells that are resistant to the
cytopathic effects of viral replication as occurs in macrophages (Ho et
al., 1986; Igarashi et al., 2001; Nicholson et al., 1986; Swingler et al.,
2007). Integrated HIV can also remain in a latent state indeﬁnitely,
without producing infectious virions, as occurs in resting CD4+ T cells
(Bukrinsky et al., 1991; Chun et al., 1995b). This latent form of
infection has a very slow apparent rate of decay in infected individuals
receiving highly active anti-retroviral therapy (HAART) (Finzi et al.,
1999; Han et al., 2007; Stevenson, 2003). Because latent provirus does
not produce signiﬁcant amounts of new particles, it is assumed to be
resistant to drug treatment and immune surveillance (Colin and VanLint, 2009; Fischer et al., 2008). The pool of resting CD4+ T cells
harboring latent provirus forms early during initial infection of a host
and represents a major obstacle for the eradication of virus from
infected patients (Chun et al., 1998).
Given the importance of integration for HIV replication and
persistence in the host, measuring this step in the viral life cycle
accurately is essential to have a better understanding of HIV biology
and pathogenesis. Measuring integration is instrumental for deter-
mining how the reservoir of latently infected resting cells forms and
how it is maintained. It may also be valuable for monitoring viral
replication in combination with other measurements, such as total
viral DNA, and for monitoring the effect of therapy on the size of the
latent reservoir. A sensitive assay for measuring integration could also
help reveal cells that may harbor viral reservoirs but at lower levels
than memory CD4+ T cells.
Our group developed a quantitative assay for measuring integration
based on Alu-PCR and repetitive sampling (O'Doherty et al., 2002; Yu et
al., 2008). The assay is sensitive and the detection limit is deﬁned by the
number of replicates performed.We routinely detect integration at levels
near 1 in 10,000 inHIV infected samples by performing 42 replicates. This
sensitivity makes the assay suitable for the detection of integration in
samples both inoculated at very low inoculum in vitro and from infected
individuals undergoing combination therapy (Agosto et al., 2007; Yu et
al., 2008). This assay incorporates a polyclonal integration standard that
parallels the diversity of integration sites found in natural infection to add
accuracy to the measurement (Brussel and Sonigo, 2003; Butler et al.,
2001; O'Doherty et al., 2002; Yu et al., 2008).
47L.M. Agosto et al. / Virology 409 (2011) 46–53Some studies suggest that total HIV DNA can be used as an
estimate of the reservoir in patients on HAART (Chomont et al., 2009;
Koelsch et al., 2008). The rationale is that total HIV DNA should
approach the level of integrated HIV DNA in patients on HAART since
unintegrated HIV DNA has a short half-life in vitro (Koelsch et al.,
2008). In order to determine if an excess of total HIV DNA exists in
some patients on HAART and to determine if the excess of total DNA is
not due to measurement error, we decided to determine the accuracy
of our integration assay. In the present study, we demonstrate that our
integration estimates are accurate and precise by comparing the level
of integration detected by quantitative PCR to the proportion of HIV-
positive clones obtained after single-cell cloning of a population of
infected cells. We go on to provide evidence that in some patients on
HAART, with undetectable plasma viral loads, there is a difference
between the levels of total and integrated HIV DNA. Therefore,
measuring total HIV DNA is not always a suitable estimate of the levels
of integrated HIV DNA and by analogy it is not always a suitable
correlate of reservoir size in patients receiving HAART. Based on these
ﬁndings, we conclude that an accuratemeasure of integrated HIV DNA
is a better indicator of reservoir size than total HIV DNA
measurements.Fig. 1. Overview of integration assay, lentiviral vector and complementary method to meas
CEM-SS inoculated in vitro. The assay involves an initial end-point PCR ampliﬁcation of t
ampliﬁcation of the HIV-containing products of the ﬁrst reaction. (B) The lentiviral vector us
Lu et al., 2004). The primers used for PCR and their relative priming sites are outlined and
performed by inoculating CEM-SS cells with VRX494 at two different viral dilutions. At 18 h
nested Alu-PCR and (ii) plated at 0.3 or 1 cell/well in round bottom 96-well plates until coloni
of HIV DNA by late reverse transcription kinetic PCR.Results
Accuracy of Alu-PCR integration assay
The assay for measuring HIV integration involves two ampliﬁca-
tion reactions: an end-point PCR ampliﬁcation and a kinetic PCR
ampliﬁcation (O'Doherty et al., 2002) (Fig. 1A). The pre-ampliﬁcation
step targets integrated HIV speciﬁcally by amplifying the region
between HIV gag and the nearest Alu repeat (see relative primer
locations in Fig. 1B). Alu repeats are the most common repetitive
elements in the human genome with a frequency of one copy every
~3000 base pairs (Jelinek and Schmid, 1982; Mighell et al., 1997).
Given that HIV integrates at various distances relative to Alu, the
distance between integrated HIV and the nearest Alu site determines
the limit of detection of the pre-ampliﬁcation step. The assay
described is capable of detecting HIV integration when it occurs
within a few thousand base pairs (2–5 kb) of the nearest Alu site
(Agosto et al., 2007). Following this pre-ampliﬁcation step, part of the
reaction product is further ampliﬁed in a second reaction that is
speciﬁc for HIV-containing amplicons. This nested-kinetic ampliﬁca-
tion recognizes the R-U5 region of the HIV long terminal repeat (seeure integration. (A) Nested Alu-PCR was used for measuring integration in samples of
he region between gag and the nearest human Alu repeat, followed by a kinetic PCR
ed for our inoculations is the HIV-based lentiviral vector, VRX494 (Humeau et al., 2004;
described below the ﬁgure. (C) A complementary method to measure integration was
post-inoculation the cells were separated into two aliquots: (i) measure integration by
es grew. Colonies were isolated approximately 2 weeks later and tested for the presence
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olds (calculated from the ampliﬁcation curves) of each reaction (see
ampliﬁcation example in Fig. 2A) is used to estimate the number of
integration events in the unknown sample by comparing the cycle
threshold to a standard curve generated using the integration
standard (Agosto et al., 2007). This standard is polyclonal, to reﬂect
the diversity of integration sites that occur in vivo, and contains one
integration event per cell. For an integration signal to be considered
positive, the average Alu-gag signal must be greater than the gag-only
signal (compare Fig. 2A to B). The gag-only control is included to
approximate the signal expected when all the DNA is unintegrated.
We determined the accuracy of the Alu-PCR integration assay by
comparing the level of integration estimated by nested Alu-PCR to the
proportion of HIV positive clones after single-cell cloning, both
obtained from the same sample of cells inoculated with HIV (Fig. 1C).
To do this, a CD4+ T cell line (CEM-SS cells) was inoculated at two
dilutions of the HIV-based lentiviral vector VRX494 (Fig. 1B) and
incubated at 37 °C. We chose to transduce the CD4+ T cell line with a
gene therapy vector to avoid the toxicity of virally encoded genes and
to ensure that only one round of infection occurred. We previously
titered our virus on the CEM-SS cell line and used viral inoculums that
should yield ~1 and ~0.2 proviruses/cell. At 16 h post-inoculation, an
integrase inhibitor was added to prevent further integration events.
Cells were then incubated for an additional 2 h at 37 °C to allow
sufﬁcient time for the integrase inhibitor to be internalized by the
cells before cloning the cells at limiting dilution. We measured
integration 2 h before, at the time of cloning (18 h) and 6 h after
cloning to demonstrate that the integrase inhibitor effectively
inhibited integration at the time of cloning. In Fig. 4, we compare
the level of integration obtained at 18 h with the level obtained by cell
cloning. As a negative control, CEM-SS were inoculated in theFig. 2.Measuring HIV integration by Alu-PCR. CEM-SS cells were inoculated with two dilution
inoculation. HIV integration was measured by Alu-PCR at 0, 16, 18 and 24 h post-inoculation.
without (A) or with (B) integrase inhibitor at 18 h post-inoculation. Plots show that a signal
occurs at an earlier cycle threshold (Ct) than when using only the primer for gag (gag-only—
to the gag-only ampliﬁcation. This conﬁrms that the gag-only signal approximates the signal
at 1× (C) and 1:5× (D) viral inoculum. Arrows indicate (a) the time point when integrase in
collected to compare the level of integrationmeasured by Alu-PCR and by single-cell cloning.
from two separate experiments. The dashed line indicates the limit of detection of integratio
(gag-only reaction) of the integrase inhibitor inoculation control between 16 and 24 h postpresence of integrase inhibitor and were kept exposed to the drug
throughout the time course.
We show the level of integration at 0, 16, 18, and 24 h post-
inoculation for two viral inoculations (Fig. 2C, D). The level of
integration appears to decay over time in the cells inoculated at a
lower dose. This could be due to slight overgrowth of the uninfected
cells after 16 h. This seems reasonable since at higher inoculum, when
practically all the cells were infected, we did not see this decay.
Alternatively, it may represent error in our assay. The actual level of
integration measured by our Alu-based PCR assay for the top dilution
at 18 h post-inoculation was 1.1 proviruses/cell and 0.39 provirus/cell
for the bottom dilution (Fig. 4B) or 0.22 (Fig. 4A). At this point, an
aliquot of cells was cloned in 96-well plates at on average 1 cell per
well (Figs. 3 and 4B) or 0.3 cells per well (Fig. 4A). Colonies of ~105
cells grew after incubating for 2 weeks. The cloning efﬁciency was
~60% when we plated at approximately 1 cell per well, which is close
to the expected 63% based on the Poisson distribution (Fig. 3). Thus,
the viral inoculum and the integrase inhibitor had a minimal effect on
the cloning efﬁciency when compared to uninfected or untreated
controls (Fig. 3). The clones were analyzed for the presence of total
HIV DNA (see relative primer position in Fig. 1B), until at least ﬁve
colonies were positive for HIV DNA. The majority of the HIV-positive
signals were between 0.1 and 1 SST/cell (see distribution of values in
Supplemental Figure 1). The range of values below 1 SST/cell can be
explained by the possibility that integration may have taken place
during the G2 stage of the cell cycle, which has been shown to be the
stage at which integration is most efﬁcient (Groschel and Bushman,
2005). At this stage of the cell cycle, a CEMss cell would have ~4 sets of
chromosomes and only one set would harbor integrated HIV DNA.
Although HIV integration appears to only have a minimal effect on
cloning efﬁciency (Fig. 3), it is possible that the daughter cellss of VRX494 1× and 1:5× with or without integrase inhibitor from the beginning of the
(A, B) Sample PCR ampliﬁcation plots of DNA from cells inoculated at 1× viral inoculum
is positive for integration when the ampliﬁcation using primers for Alu-gag (gray lines)
black lines). The Alu-gag signal obtained with an integrase inhibitor gave a similar signal
expected when there is no integration. (C, D) Integration time course in cells inoculated
hibitor was added to block further integration and (b) the time point when cells were
Error bars indicate the standard deviation of the combinedmeasurements of integration
n. This limit is the average level of ampliﬁcation obtained from the PCR negative control
-inoculation.
Fig. 3. Infection of CEM-SS with VRX494 or treatment with integrase inhibitor
minimally affects cloning efﬁciency. Cloning efﬁciency was determined by calculating
the percentage of wells in which cell colonies grew with cloning at ~1 cell/well under
the following conditions: viral inoculum with integrase inhibitor added at 16 h,
uninfected without integrase inhibitor, uninfected with integrase inhibitor and infected
without integrase inhibitor (1× viral dilution). Error bars represent the standard
deviation of the combined data of two separate experiments.
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efﬁciencies, thus affecting the relative proportion of HIV-positive and
HIV-negative cells within the colony.
We then sought to determine if the two methods of quantitation
would yield similar results. We foundwhen we plated cells at 0.3 cells
per well (single cell cloning conditions) and with a low proviral level
(0.22 proviruses per cell by our Alu-PCR based assay), both methods
gave similar results (Fig. 4A). We obtained 0.22 proviruses per cell by
our integration assay and 0.17 (17%) of cloneswere positive for HIV by
single cell cloning. We also cloned the cells at higher levels of
integration (1.1 proviruses per cell and 0.39 proviruses per cell) and at
a higher concentration of cells (on average 1 cell/well) (Fig. 4B). We
found that 56% of the nonempty wells were positive for HIV at 1.1Fig. 4. The estimate of integration measured by nested Alu-PCR, closely correlates with the p
cells. (A) Comparison of integration measured by Alu-PCR and by cell cloning when the cell
integration detected by Alu-PCR was converted into an estimate of HIV-positive nonempt
multiply-infected cells and wells containing multiple clones at the time of cloning. The st
nonempty wells were calculated with the binomial distribution formula. (C) Comparison of
values of (A) and (B) at each virus concentration after values were normalized to the level
Student's t-test.proviruses per cell and ~23% were positive at 0.39 proviruses per cell
by counting the number of nonempty wells that were positive for HIV.
At these higher inoculums, we needed to perform two corrections
before we could compare the two methods: we needed to ﬁrst
compensate for multiply infected cells and then to compensate for the
increased probability of multiple clones per well. We did not need to
make these corrections, when we cloned the cells at 0.3 cells/well
with 0.22 proviruses per cell since the chance of multiply infected
cells and multiple clones per well was low. In Supplement 2, we
provide a detailed description of howwe converted the proviruses per
cell as estimated by Alu-PCR to the predicted percentage of nonempty
wells that were positive for HIV. Brieﬂy, we converted the proviral
number to the expected number of clones that would be infected
whichwas then converted to the number of nonempty wells expected
to be positive for HIV (Fig. 4B). Finally, we normalized the number of
nonempty wells that were positive for HIV to the level of infection by
dividing by the number of reverse transcripts present at the time of
cloning. We averaged these measurements and performed a Student's
t-test and found the measurement by both methods were not
signiﬁcantly different (Fig. 4C).
An excess of total DNA is present in a subset of patients receiving HAART
Because unintegrated HIV DNA has a short half-life in vitro, it
stands to reason that the level of total HIV DNA could approach the
level of integrated HIV DNA after prolonged HAART. In other words,
the ratio of total over integrated should approach 1. Studies support
that this indeed occurs at least in some patients on HAART (Chomont
et al., 2009; Koelsch et al., 2008). We wanted to determine how often
total HIV DNA and integrated HIV DNA are equivalent in patients after
at least 1 year of suppressive HAART therapy. To do this, we needed to
account for measurement errors of total HIV DNA and integrated HIV
DNA since some elevated ratios could be due to measurement error.
To determine the error in our measurements, we used our integration
standard, which was designed to have a ratio of 1 total HIV DNA per
integrated DNA since all the HIV is integrated in our standard (Agosto
et al., 2007). Thus, any variation from this value would be due toroportion of HIV-positive colonies obtained after single-cell cloning of infected CEM-SS
s were infected at low inoculum and single-cell cloned at 0.3 cells/well. (B) The level of
y wells using the Poisson distribution formula (see Supplement 2). This corrects for
andard deviation for the Poisson-based estimate and the actual percent HIV-positive
predicted vs. actual HIV positive nonempty wells. Graph represents the combination of
of late reverse transcription (SST) of each inoculation. p-values were calculated using
Table 2
Patient background. Provides the range of CD4 counts during the year the patients viral
load and CD4 counts were monitored every 3 months. The nadir CD4 for patients is
prior to treatment.
Patient ID
number
CD4
counta
Count
collectionb
Nadir
CD4c
Viral
loadd
Drug regimene
1 657–780 689 156 b75 EFV, ABC,
ZDV,3TC
2 208–435 435 172 b75 EFV, 3TC D4T
3 386–651 611 N/A b75 EFV, ABC, 3TC
4 197–317 315 34 b75 EFV, ABC, ZDV,
3TC
5 538–752 725 38 b75 EFV, D4T,DDI
6 269–385 321 N/A b75 EFV, ZDV, 3TC
7 399–527 399 N/A b75 EFV, ABC, 3TC,
TDF
a CD4 cell count (cells/ml) was monitored every 3 months for the length of the study
(12 months).
b CD4 cell count (cells/ml) at the time of sample collection for PCR analysis
(12 months).
c Nadir count (cells/ml) detected at least 7 months prior to starting in the study.
d Viral load (RNA copies/ml) was measured every 3 months for the length of the
study. Viral load was never detected above the limit of detection (75 copies/ml).
e Efavirenz (EFV), Abacavir (ABC), Zidovudine (ZDV), Lamivudine (3TC), Stavudine
(d4T), Didanosine (DDI), Tenofovir (TDF).
50 L.M. Agosto et al. / Virology 409 (2011) 46–53errors. To mimic the conditions in a patient sample, we diluted our
integration standard so that there was 1 integration standard cell in
10,000 uninfected cells. Total DNA and integrated HIV DNA were
measured seven times. The ratio of total DNA over integrated DNA
obtained was 0.93±0.40 (Table 1). Because the levels of total DNA
were measured independently from the levels of integrated HIV DNA,
it is not completely appropriate tomatch any individual measurement
of total HIV DNAwith any individual measurement of integrated DNA.
For this reason, we also calculated the average total and the average
integrated HIV DNA and then calculated the ratio of total over
integrated. We also calculated the standard deviation using a formula
for propagating error in quotients (Lindberg, 2010). Using this
method, we obtained a ratio of total over integrated of 0.8±0.5.
Finally, we also combined every permutation of total over integrated
measurements from our seven replicates and found that the ratios
ranged from 0.3 to 1.9 with a 96% conﬁdence interval of 0.4 to 1.9.
Thus, all three methods gave similar conﬁdence intervals. We decided
conservatively, that a ratio greater than 2.1 (pb0.01, using the
standard deviation from our most conservative estimate in Table 1)
would be indicative of a true excess.
We evaluated if the estimate of total HIV DNA correlates with the
level of integrated DNA in PBMC from closely monitored individuals
receiving suppressive HAART. The patients have been on HAART for at
least a year on an efavirenz-based regimen along with two to three
nucleoside analogs (Table 2). The patients sustained undetectable
viral loads (b75 RNA copies/ml) for at least a year and the viral load
was monitored every 3 months prior to PBMC sample collection and
analysis. We then measured integration by Alu-PCR in samples from
patients on HAART. We found a signiﬁcant excess of total HIV DNA in
three out of seven patients (Fig. 5), suggesting that the total HIV DNA
levels do not always correlate with the level of HIV integration in
patients on HAART. Our results also suggests that excesses of total
over integrated DNA may occur commonly in treated patients which
may have implications for understanding latency and reservoir
maintenance in the presence of effective therapy.Table 1
Calculating the measurement error of total over integrated HIV DNA, to determine the
ratio that indicates real excesses of unintegrated HIV DNA.
In this experiment, a master stock of our integration standard (IS) diluted in PBMC DNA
was used to mimic a patient sample (1 copy of IS in 10,000 PBMC). DNA corresponding
to 2×106 cells, 1×106 and 0.2×106 was assayed for total DNA (SST/cell) 7 times with
10 replicates per assay. DNA corresponding to 7.5×103 cells was assayed for integrated
DNA seven times with 42 replicates per assay. The assays were then paired in the order
that they were performed. These pairings were then averaged and the standard
deviation was calculated. Using these numbers, we calculated that a signiﬁcant excess
occurs when the ratio is greater than 2.0 (using 2.58 standard deviations, for a
p=0.01). We also averaged the measurements for total HIV DNA and divided that
number by the average number of proviruses and then calculated a standard deviation.
Using this method, we calculated that a signiﬁcant excess occurred when the ratio was
greater than 2.1 (i.e. 2.58 standard deviations above the mean, p=0.01).
Experiment
number
HIV copies per 10,000
cells (n=10)
Provirus copies per
10,000 cells (n=42)
Ratio SST/
Provirus
1 1.01 0.68 1.49
2 1.27 0.86 1.48
3 1.28 2.45 0.52
4 0.95 1.46 0.65
5 0.92 1.31 0.70
6 0.83 0.86 0.97
7 0.90 1.27 0.71
Average 1.02 1.27
Average ratioa 0.81 Average ratiob 0.93
Standard deviation 0.5 Standard deviation 0.40
p=0.01 cutoff 2.10 p=0.01 cutoff 1.96
a Average of HIV copies per 10,000 cells for seven experiments divided by average of
provirus copies per 10,000 cells for seven experiments.
b Average of individual ratios for each of the seven experiments.Discussion
Many studies have measured integration in patient samples
providing useful information about the pathogenesis of HIV (Chun
et al., 1995a, 1997; Ibanez et al., 1999; Izopet et al., 2002; Ostrowski et
al., 1999). We recently also described an assay that was suitable for
clinical samples (Liszewski et al., 2009b; Yu et al., 2008). In the
present study, we set out to determine the accuracy and precision
(error) of our integration assay and applied it to samples from HIV
infected patients on HAART to determine how frequently an excess of
unintegrated HIV DNA can be detected. While our prior work
demonstrated that our integration assay can discriminate between
integrated and unintegrated HIV DNA (Yu et al., 2008), here we
demonstrate that our Alu-PCR integrationmeasurement is accurate by
comparing it to the proportion of HIV DNA-positive clones after single
cell cloning. This indicates that our Alu-PCR provides reliable
measurements of integration from samples obtained from HIV-
infected patients or from cells inoculated in vitro. Using this assay,
we demonstrate that in a subset of patients on suppressive HAART
there is an excess of unintegrated HIV DNA.Fig. 5. An excess of total DNA exists in a subset of patients receiving HAART. Total (SST)
and integrated DNA were measured in PBMC samples from patients on HAART. The
numbers above each black bar represents the ratio of total DNA over integrated DNA.
The numbers with asterisks indicate measurements that show a true excess of
unintegrated HIV DNA. These ratios are greater than 2.58 standard deviations above the
integration standard ratio for a pN0.01. We measured 15,000 genomes per well to
measure integration (7500 cell equivalents). We measured 0.2–2×106 cell equivalents
for total, depending on sample availability. Error bars represent the standard deviation
of 3 measurements of total DNA and 42 measurements of integrated DNA.
51L.M. Agosto et al. / Virology 409 (2011) 46–53Many exciting approaches for stimulating out reservoirs are being
investigated (Coiras et al., 2009; Colin and Van Lint, 2009; Dahl and
Palmer, 2009). As eradicating HIV reservoirs becomes a goal and as
treatments that target reservoirs become available, it will become even
more important to accurately measure the reservoir. HIV integration
levels may be a good surrogate marker for reservoirs and therefore
measuring integration accurately could be used to monitor treatments
that target reservoirs. As therapies are in development, ideally we would
want sensitive assays able to detect small changes in reservoir size; an
assay with a small error would be able to detect smaller changes. We
found in some patients on HAART the level of total HIV approached the
level of integrated HIV DNA consistent with previous work (Chomont et
al., 2009; Koelsch et al., 2008). However, we also found patients where
total was in excess of integrated. Given that excesses do occur in some
patients, we suggest measuring total HIV DNA in patients receiving
HAART is not always representative of viral reservoirs.
Measuring total HIV DNA in PBMCs from patients is one of the
common methods for monitoring reservoir size. However, as shown
here, there is variability in the level of total DNA relative to the level of
integrated DNA. Another method employed for estimating the size of
the reservoir is the infectious units per million-assay (IUPM)
(Siliciano and Siliciano, 2005). This method involves serial dilution
of stimulated PBMC from an infected individual followed by culturing
the diluted cells in the presence of activated CD4+ T blasts. The IUPM
assay, while powerful, is costly, laborious, with inherentlywide errors,
and thus, not ideal for monitoring the reservoir size in HIV infected
individuals routinely. Therefore, we propose that measuring integra-
tion may be a more feasible method for routinely monitoring the
effect of treatment on reservoir size. This method could also be
employed for determining if novel drugs that target the reservoir
directly, such as histone deacetylase inhibitors, can decrease the level
of integration over time as an indirect measure of reservoir size
(Archin et al., 2009; Lehrman et al., 2005). However, because the
number of replication competent proviruses has been estimated to be
far less than the quantity of integrated HIV DNA, it is possible that the
reservoir size would not correlate with the number of integration
events. Future work will be required to determine if measuring
integration correlates with reservoir size as measured by the
Infectious Unit Per Million (IUPM) assay. Nonetheless, we reason
measuring total and integrated HIV DNA may still be useful since
excesses of unintegrated HIV DNA may be physiologically relevant. It
is currently unclear what an excess of unintegrated HIV DNA indicates
or what processes lead to the excess. Because total DNA has a short
half-life in vitro (Koelsch et al., 2008), this excess of total DNA over
integrated DNA may represent new rounds of infection, as previously
proposed (Koelsch et al., 2008). This would suggest that some low
level of viral replication might be taking place in some patients
despite suppressive therapy. This low level of ongoing viral replication
could contribute to the replenishment of the latent reservoir in at least
a subset of patients (Buzon et al., 2010; Ramratnam et al., 2000;
Ramratnam et al., 2004). Any level of viral replication would have to
be quite low, because several studies indicate that drug resistance
does not frequently develop on HAART (Hermankova et al., 2001;
Persaud et al., 2004) and viral evolution cannot be detected in many
patients on HAART (Kieffer et al., 2004; Nettles et al., 2004; Nottet et
al., 2009; Shen and Siliciano, 2008; Tobin et al., 2005). Alternative
explanations, such as undetected viral blips or undetected low level
viremia and 2-LTR circles that have accumulated over time prior to the
initiation of therapy, could also account for this excess of total HIV
DNA. Some studies suggest these 2-LTR forms aremore stable forms at
least in vitro (Butler et al., 2002; Pierson et al., 2002) and thus could
potentially accumulate in vivo, though there is also evidence that
these forms may be less stable in vivo than in vitro (Sharkey et al.,
2005). More work would be required to determine the true nature of
this excess of total HIV DNA, under what circumstance does it occur
and how often does it occur. If this excess represents new rounds ofreplication, monitoring the level of both integrated and total HIV DNA
using assays similar to the ones that we described could be useful as a
cost effective, sensitive and reliable method for detecting ongoing
replication in patients receiving HAART.
Materials and methods
Cell line and virus
The CD4+ T lymphoblastoid cell line CEM-SS, a subclonal cell line
derived from the CEM cell line (Foley et al., 1965; Nara and Fischinger,
1988), was maintained at 1–5×105 cells/ml. The culture medium
used to maintain the cells was RPMI 1640 (Invitrogen) supplemented
with 10% heat inactivated FBS (Invitrogen) and 100 μg/ml of
penicillin–streptomycin (Mediatech Inc.). The lentiviral vector
VRX494 was pseudotyped with VSV-G and was donated by VIRxSYS
(Humeau et al., 2004; Lu et al., 2004).
Cell inoculations
The cells were inoculated with VRX494 in 48-well ﬂat-bottom
plates at 5×105 cells/ml by spinoculation (1200×g, 25 °C, 2 h)
(O'Doherty et al., 2000). The viral inoculum was diluted to give a
relative activity of 1.1, 0.39 or 0.22 proviruses/cell. After inoculation,
the cells were washed twice to remove unbound virus and were
resuspended in culture medium. The cells were then incubated at
37 °C and aliquots of cells were collected at 0, 16, 18 and 24 h post-
inoculation for measuring the level of integration. The integrase
inhibitor raltegravir (obtained from AIDS Research and Reference
Reagents Program, NIAID, catalog #11680 and donated by Merck &
Co., Inc.) or L870,812 (donated by Merck & Co., Inc.) was added to the
cells at 16 h post-inoculation to prevent any further integration
events. Raltegravir added at 1 μM (three cloning experiment) or
L870,812 (two cloning experiment) added at 0.8 μM inhibit integra-
tion at N90%. At 18 h post-inoculation, cells were collected for both
measuring integration and for single-cell cloning.
Measuring total and integrated HIV DNA
Total HIV DNA represents the level of reverse transcripts that have
completed the second strand transfer step (SST). Total HIV DNA was
measured by kinetic PCR in 20 μl reaction volumes, following the
conditions and protocol previously described (Swiggard et al., 2005).
The following primers were used: HIV-U5 Forward primer 5′
GCCTCAATAAAGCTTGCCTTGAGTG-3′ and HIV-gag reverse primer 5′
CAGCAAGCCAGATCCTGCG-3′. The kinetic PCR probe used is 5′FAM-
CCAGAGTCACACAACAGACG-TAMRA 3′. HIV integration was mea-
sured following the conditions and protocol previously described
(Agosto et al., 2009), but using different primers which are described
in O'Doherty et al. (2002). For the patient samples a slightly different
protocol was used as described (Liszewski et al., 2009a,b). Cell
numbers were estimated by measuring the number of β-globin copies
per DNA sample by kinetic PCR (O'Doherty et al., 2000). In our
previous study (Agosto et al., 2007), we reported that 25 μl at 2 μg/ml
was equivalent to 15,000 genomes, which is equivalent to 7500
diploid cells. In our prior paper, we occasionally substituted the word
“cells” incorrectly when we intended the word “genomes” since there
are two genomes per diploid cell. The kinetic PCR instrument used is
the ABI 7500 Fast Real-Time PCR System.
Single-cell cloning
At 18 h post-inoculation, an aliquot of cells was diluted to 10 or
3 cells/ml. A 100 μl of this diluted cell aliquot was plated in 96-well
round bottom plates to obtain on average 1 or 0.3 cells per well.
Colonies were allowed to grow for ~2 weeks in the presence of
52 L.M. Agosto et al. / Virology 409 (2011) 46–53integrase inhibitor, reaching a density of ~104–105 cells/well. Cells
from individual wells were collected and DNA was puriﬁed using the
QIAamp DNAMicro Kit (Qiagen). The DNA samples were then assayed
for HIV late reverse transcripts. Colonies were assayed for HIV late
reverse transcripts until at least ﬁve colonies were positive. A signal
was considered positive for HIV DNA if the level was above the
detection limit of the total DNA assay (0.0001SST/cell), when DNA
from 104 cells were assayed in duplicate.
Data analysis
Microsoft Excelwas used for data analysis and the statistics software
MyStat 12 was used to prepare the box plot shown in Supplemental
Figure 1.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.08.024.
The following are the supplementary materials related to this
article.Supplemental Figure 1. Distribution of HIV-positive signals. The
majority of the colonies positive for HIV DNA had 0.1–1 SST/cell.
Asterisks indicate outlying values. A total of 17 and 24 values are
represented in the box plot for cells inoculated at 1× and 1:5× viral
inoculum respectively.Supplementary materials
Acknowledgments
We gratefully acknowledge Daria Hazuda for her intellectual
contributions and the CFAR at Penn for reagents and facilities. We
thank Michele Di Mascio for helpful discussions on measurement of
error in our system. We thank Robert Gross and Jennifer Chapman for
providing patient samples. We thank Laurent Humeau and Nikolay
Kirokhov for providing uswith VRX494 pseudotypedwith VSV-G. This
work was supported by Merck, PKC Pharmaceuticals and NIH grants
7-K08-AI-073102-02, 5K02AI078766-03, R21 AI081215-01 A1, and
T32AI07324.
References
Agosto, L.M., Yu, J.J., Dai, J., Kaletsky, R., Monie, D., O'Doherty, U., 2007. HIV-1 integrates
into resting CD4+ T cells even at low inoculums as demonstrated with an
improved assay for HIV-1 integration. Virology 368 (1), 60–72.
Agosto, L.M., Yu, J.J., Liszewski, M.K., Baytop, C., Korokhov, N., Humeau, L.M., O'Doherty,
U., 2009. The CXCR4-tropic human immunodeﬁciency virus envelope promotes
more-efﬁcient gene delivery to resting CD4+ T cells than the vesicular stomatitis
virus glycoprotein G envelope. J. Virol. 83 (16), 8153–8162.
Ansari-Lari, M.A., Donehower, L.A., Gibbs, R.A., 1995. Analysis of human immunode-
ﬁciency virus type 1 integrase mutants. Virology 211 (1), 332–335.
Archin, N.M., Keedy, K.S., Espeseth, A., Dang, H., Hazuda, D.J., Margolis, D.M., 2009.
Expression of latent human immunodeﬁciency type 1 is induced by novel and
selective histone deacetylase inhibitors. Aids 23 (14), 1799–1806.
Brussel, A., Sonigo, P., 2003. Analysis of early human immunodeﬁciency virus type 1
DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J.
Virol. 77 (18), 10119–10124.
Bukrinsky, M.I., Stanwick, T.L., Dempsey, M.P., Stevenson, M., 1991. Quiescent T
lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254,
423–427.
Butler, S.L., Hansen, M.S.T., Bushman, F.D., 2001. A quantitative assay for HIV DNA
integration in vivo. Nat. Med. 7, 631–634.
Butler, S.L., Johnson, E.P., Bushman, F.D., 2002. Human immunodeﬁciency virus cDNA
metabolism: notable stability of two-long terminal repeat circles. J. Virol. 76 (8),
3739–3747.
Buzon, M.J., Massanella, M., Llibre, J.M., Esteve, A., Dahl, V., Puertas, M.C., Gatell, J.M.,
Domingo, P., Paredes, R., Sharkey,M., Palmer, S., Stevenson,M., Clotet, B., Blanco, J., and
Martinez-Picado, J., 2010. HIV-1 replication and immune dynamics are affected by
raltegravir intensiﬁcation of HAART-suppressed subjects. Nat. Med. 16 (4), 460–465.
Cara, A., Guarnaccia, F., Reitz, M.S., Gallo, R.C., Lori, F., 1995. Self-limiting, cell type-
dependent replication of an integrase-defective human immunodeﬁciency virus
type 1 in human primary macrophages but not T lymphocytes. Virology 208 (1),
242–248.
Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F.A., Yassine-Diab, B.,
Boucher, G., Boulassel, M.R., Ghattas, G., Brenchley, J.M., Schacker, T.W., Hill, B.J.,
Douek, D.C., Routy, J.P., Haddad, E.K., Sekaly, R.P., 2009. HIV reservoir size and
persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15
(8), 893–900.Chun, T.-W., Finzi, D., Margolick, J., Chadwick, K., Schwartz, D., Siliciano, R.F., 1995a. In
vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable
latency. Nat. Med. 1, 1284–1290.
Chun, T.W., Finzi, D., Margolick, J., Chadwick, K., Schwartz, D., Siliciano, R.F., 1995b. In
vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable
latency. Nat. Med. 1 (12), 1284–1290.
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M.,
Chadwick, K., Margolick, J., Quinn, T.C., Kuo, Y.-H., Brookmeyer, R., Zeiger, M.A.,
Barditch-Crovo, P., Siliciano, R.F., 1997. Quantiﬁcation of latent tissue reservoirs and
total body viral load in HIV-1 infection. Nature 387, 183–188.
Chun, T.W., Engel, D., Berrey, M.M., Shea, T., Corey, L., Fauci, A.S., 1998. Early
establishment of a pool of latently infected, resting CD4(+) T cells during primary
HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869–8873.
Cofﬁn, J.M., 1997. In: Cofﬁn, J.M., Hughes, S.H., Varmus, H.E. (Eds.), Retroviruses. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Coiras, M., Lopez-Huertas, M.R., Perez-Olmeda, M., Alcami, J., 2009. Understanding HIV-
1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev.
Microbiol. 7 (11), 798–812.
Colin, L., Van Lint, C., 2009. Molecular control of HIV-1 postintegration latency:
implications for the development of new therapeutic strategies. Retrovirology 6, 111.
Dahl, V., Palmer, S., 2009. Establishment of drug-resistant HIV-1 in latent reservoirs. J.
Infect. Dis. 199 (9), 1258–1260.
Engelman, A., Englund, G., Orenstein, J.M., Martin, M.A., Craigie, R., 1995. Multiple
effects of mutations in human immunodeﬁciency virus type 1 integrase on viral
replication. J. Virol. 69, 2729–2736.
Englund, G., Theodore, T.S., Freed, E.O., Engelman, A., Martin, M.A., 1995. Integration is
required for productive infection of monocyte-derived macrophages by Human
Immunodeﬁciency Virus type 1. J. Virol. 69, 3216–3219.
Finzi, D., Blankson, J., Siliciano, J.D., Margolick, J.B., Chadwick, K., Pierson, T., Smith, K.,
Lisziewicz, J., Lori, F., Flexner, C., Quinn, T.C., Chaisson, R.E., Rosenberg, E.,Walker, B.,
Gange, S.J., Gallant, J., Siliciano, R.F., 1999. Latent infection of CD4+ T cells provides
a mechanism for lifelong persistence of HIV-1, even in patients on effective
combination therapy. Nat. Med. 5, 512–517.
Fischer, M., Joos, B., Niederost, B., Kaiser, P., Hafner, R., von Wyl, V., Ackermann, M.,
Weber, R., Gunthard, H.F., 2008. Biphasic decay kinetics suggest progressive
slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.
Retrovirology 5, 107.
Foley, G.E., Handler, A.H., Lynch, P.M., Wolman, S.R., Stolberg, C.S., Eagle, H., 1965. Loss
of neoplastic properties in vitro: II. Observations on KB sublines. Cancer Res. 25,
1254–1261.
Groschel, B., Bushman, F., 2005. Cell cycle arrest in G2/M promotes early steps of
infection by human immunodeﬁciency virus. J. Virol. 79 (9), 5695–5704.
Han, Y., Wind-Rotolo, M., Yang, H.C., Siliciano, J.D., Siliciano, R.F., 2007. Experimental
approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 5 (2), 95–106.
Hermankova, M., Ray, S.C., Ruff, C., Powell-Davis, M., Ingersoll, R., D'Aquila, R.T., Quinn,
T.C., Siliciano, J.D., Siliciano, R.F., Persaud, D., 2001. HIV-1 drug resistance proﬁles in
children and adults with viral load of b50 copies/ml receiving combination therapy.
Jama 286 (2), 196–207.
Ho, D.D., Rota, T.R., Hirsch, M.S., 1986. Infection of monocyte/macrophages by human T
lymphotropic virus type III. J. Clin. Investig. 77, 1712–1715.
Humeau, L.M., Binder, G.K., Lu, X., Slepushkin, V., Merling, R., Echeagaray, P., Pereira, M.,
Slepushkina, T., Barnett, S., Dropulic, L.K., Carroll, R., Levine, B.L., June, C.H., Dropulic,
B., 2004. Efﬁcient lentiviral vector-mediated control of HIV-1 replication in CD4
lymphocytes from diverse HIV+ infected patients grouped according to CD4 count
and viral load. Mol. Ther. 9 (6), 902–913.
Ibanez, A., Puig, T., Elias, J., Clotet, B., Ruiz, L., Martinez, M.A., 1999. Quantiﬁcation of
integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy
in HIV-1-infected patients. Aids 13 (9), 1045–1049.
Igarashi, T., Brown, C.R., Endo, Y., Buckler-White, A., Plishka, R., Bischofberger, N.,
Hirsch, V., Martin, M.A., 2001. Macrophage are the principal reservoir and sustain
high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly
pathogenic simian immunodeﬁciency virus/HIV type 1 chimera (SHIV): implica-
tions for HIV-1 infections of humans. Proc. Natl Acad. Sci. USA 98 (2), 658–663.
Izopet, J., Cazabat, M., Pasquier, C., Sandres-Saune, K., Bonnet, E., Marchou, B., Massip, P.,
Puel, J., 2002. Evolution of total and integrated HIV-1 DNA and change in DNA
sequences in patients with sustained plasma virus suppression. Virology 302 (2),
393–404.
Jelinek, W.R., Schmid, C.W., 1982. Repetitive sequences in eukaryotic DNA and their
expression. Annu. Rev. Biochem. 51, 813–844.
Kieffer, T.L., Finucane, M.M., Nettles, R.E., Quinn, T.C., Broman, K.W., Ray, S.C., Persaud,
D., Siliciano, R.F., 2004. Genotypic analysis of HIV-1 drug resistance at the limit of
detection: virus production without evolution in treated adults with undetectable
HIV loads. J. Infect. Dis. 189 (8), 1452–1465.
Koelsch, K.K., Liu, L., Haubrich, R., May, S., Havlir, D., Gunthard, H.F., Ignacio, C.C.,
Campos-Soto, P., Little, S.J., Shafer, R., Robbins, G.K., D'Aquila, R.T., Kawano, Y.,
Young, K., Dao, P., Spina, C.A., Richman, D.D., Wong, J.K., 2008. Dynamics of total,
linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J. Infect. Dis.
197 (3), 411–419.
Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., Landay, A.L.,
Coombs, R.W., Richman, D.D., Mellors, J.W., Cofﬁn, J.M., Bosch, R.J., Margolis, D.M.,
2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet
366 (9485), 549–555.
Lindberg, V., 2010. Manual on Uncertainties, Graphing, and the Vernier Caliper. http://
www.rit.edu/cos/uphysics/uncertainties/Uncertaintiespart2.html.
Liszewski, M.K., Graf, E.H., Mexas, A.M., Yu, J.J., Migueles, S.A., O'Doherty, U., 2009a.
Symposium on Antiviral Drug Resistance. Richmond, Virginia, USA.
53L.M. Agosto et al. / Virology 409 (2011) 46–53Liszewski, M.K., Yu, J.J., O'Doherty, U., 2009b. Detecting HIV-1 integration by repetitive-
sampling Alu-gag PCR. Methods 47 (4), 254–260.
Lu, X., Humeau, L., Slepushkin, V., Binder, G., Yu, Q., Slepushkina, T., Chen, Z., Merling, R.,
Davis, B., Chang, Y.N., Dropulic, B., 2004. Safe two-plasmid production for the ﬁrst
clinical lentivirus vector that achieves N99% transduction in primary cells using a
one-step protocol. J. Gene Med. 6 (9), 963–973.
Mighell, A.J., Markham, A.F., Robinson, P.A., 1997. Alu sequences (Minireview). FEBS
Lett. 417, 1–5.
Nara, P.L., Fischinger, P.J., 1988. Quantitative infectivity assay for HIV-1 and -2. Nature
332, 469–470.
Nettles, R.E., Kieffer, T.L., Simmons, R.P., Cofrancesco Jr., J., Moore, R.D., Gallant, J.E.,
Persaud, D., Siliciano, R.F., 2004. Genotypic resistance in HIV-1-infected patients
with persistently detectable low-level viremia while receiving highly active
antiretroviral therapy. Clin. Infect. Dis. 39 (7), 1030–1037.
Nicholson, J.K., Cross, G.D., Callaway, C.S., McDougal, J.S., 1986. In vitro infection of
human monocytes with human T lymphotropic virus type III/lymphadenopathy-
associated virus (HTLV-III/LAV). J. Immunol. 137 (1), 323–329.
Nottet, H.S., van Dijk, S.J., Fanoy, E.B., Goedegebuure, I.W., de Jong, D., Vrisekoop, N., van
Baarle, D., Boltz, V., Palmer, S., Borleffs, J.C., Boucher, C.A., 2009. HIV-1 can persist in
aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years
of effective highly active antiretroviral therapy. J. Acquir. Immune Deﬁc. Syndr. 50
(4), 345–353.
O'Doherty, U., Swiggard, W.J., Malim, M.H., 2000. Human immunodeﬁciency virus type
1 spinoculation enhances infection through virus binding. J. Virol. 74 (21),
10074–10080.
O'Doherty, U., Swiggard, W.J., Jeyakumar, D., McGain, D., Malim, M.H., 2002. A sensitive,
quantitative, assay for Human Immunodeﬁciency Virus type 1 integration. J. Virol.
76 (21), 10,942–10,950.
Ostrowski, M.A., Chun, T.-W., Justement, S.J., Motola, I., Spinelli, M.A., Adelsberger, J.,
Ehler, L.A., Mizell, S.B., Hallahan, C.W., Fauci, A.S., 1999. Both memory and CD45RA
(+)/CD62L(+) naive CD4(+) T cells are infected in human immunodeﬁciency
type 1-infected individuals. J. Virol. 73, 6430–6435.
Persaud, D., Siberry, G.K., Ahonkhai, A., Kajdas, J., Monie, D., Hutton, N., Watson, D.C.,
Quinn, T.C., Ray, S.C., Siliciano, R.F., 2004. Continued production of drug-sensitive
human immunodeﬁciency virus type 1 in children on combination antiretroviral
therapy who have undetectable viral loads. J. Virol. 78 (2), 968–979.
Pierson, T.C., Kieffer, T.L., Ruff, C.T., Buck, C., Gange, S.J., Siliciano, R.F., 2002. Intrinsic
stability of episomal circles formed during Human Immunodeﬁciency Virus Type-1
replication. J. Virol. 76 (8), 4138–4144.
Ramratnam, B., Mittler, J.E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C.A.,
Perelson, A.S., Markowitz, M., Ho, D.D., 2000. The decay of the latent reservoir of
replication-competent HIV-1 is inversely correlated with the extent of residual
viral replication during prolonged anti-retroviral therapy. Nat. Med. 6, 82–85.Ramratnam, B., Ribeiro, R., He, T., Chung, C., Simon, V., Vanderhoeven, J., Hurley, A.,
Zhang, L., Perelson, A.S., Ho, D.D., Markowitz, M., 2004. Intensiﬁcation of
antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and
decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immune
Deﬁc. Syndr. 35 (1), 33–37.
Sakai, H., Kawamura, M., Sakuragi, J., Sakuragi, S., Shibata, R., Ishimoto, A., Ono, N., Ueda,
S., Adachi, A., 1993. Integration is essential for efﬁcient gene expression of human
immunodeﬁciency virus type 1. J. Virol. 67 (3), 1169–1174.
Sharkey, M., Triques, K., Kuritzkes, D.R., Stevenson, M., 2005. In vivo evidence for
instability of episomal human immunodeﬁciency virus type 1 cDNA. J. Virol. 79 (8),
5203–5210.
Shen, L., Siliciano, R.F., 2008. Viral reservoirs, residual viremia, and the potential of
highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin.
Immunol. 122 (1), 22–28.
Siliciano, J.D., Siliciano, R.F., 2005. Enhanced culture assay for detection and
quantitation of latently infected, resting CD4+ T-cells carrying replication-
competent virus in HIV-1-infected individuals. Meth. Mol. Biol. 304, 3–15.
Stevenson, M., 2003. HIV-1 pathogenesis. Nat. Med. 9 (7), 853–860.
Stevenson, M., Haggerty, S., Lamonica, C.A., Meier, C.M., Welch, S.K., Wasiak, A.J., 1990a.
Integration is not necessary for expression of human immunodeﬁciency virus type
1 protein products. J. Virol. 64 (5), 2421–2425.
Stevenson, M., Stanwick, T.L., Dempsey, M.P., Lamonica, C.A., 1990b. HIV-1 replication is
controlled at the level of T cell activation and proviral integration. Eur. Mol. Biol.
Organ. J. 9, 1551–1560.
Swiggard, W.J., Baytop, C., Yu, J.J., Dai, J., Li, C., Schretzenmair, R., Theodosopoulos, T.,
O'Doherty, U., 2005. Human immunodeﬁciency virus type 1 can establish latent
infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79
(22), 14179–14188.
Swingler, S., Mann, A.M., Zhou, J., Swingler, C., Stevenson, M., 2007. Apoptotic killing of
HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS
Pathog. 3 (9), 1281–1290.
Tobin, N.H., Learn, G.H., Holte, S.E., Wang, Y., Melvin, A.J., McKernan, J.L., Pawluk, D.M.,
Mohan, K.M., Lewis, P.F., Mullins, J.I., Frenkel, L.M., 2005. Evidence that low-level
viremias during effective highly active antiretroviral therapy result from two
processes: expression of archival virus and replication of virus. J. Virol. 79 (15),
9625–9634.
Wiskerchen, M., Meusing, M.A., 1995. Identiﬁcation and characterization of a
temperature-sensitive mutant of human immunodeﬁciency virus type 1 by alanine
scanning mutagenesis of the integrase gene. J. Virol. 69, 597–601.
Yu, J.J., Wu, T.L., Liszewski, M.K., Dai, J., Swiggard, W.J., Baytop, C., Frank, I., Levine, B.L.,
Yang, W., Theodosopoulos, T., O'Doherty, U., 2008. A more precise HIV integration
assay designed to detect small differences ﬁnds lower levels of integrated DNA in
HAART treated patients. Virology 379 (1), 78–86.
